IBDEI1WJ ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33803,0)
 ;;=M96.0^^191^1976^16
 ;;^UTILITY(U,$J,358.3,33803,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33803,1,3,0)
 ;;=3^Pseudarthrosis after fusion or arthrodesis
 ;;^UTILITY(U,$J,358.3,33803,1,4,0)
 ;;=4^M96.0
 ;;^UTILITY(U,$J,358.3,33803,2)
 ;;=^5015373
 ;;^UTILITY(U,$J,358.3,33804,0)
 ;;=R20.2^^191^1976^1
 ;;^UTILITY(U,$J,358.3,33804,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33804,1,3,0)
 ;;=3^Paresthesia of skin
 ;;^UTILITY(U,$J,358.3,33804,1,4,0)
 ;;=4^R20.2
 ;;^UTILITY(U,$J,358.3,33804,2)
 ;;=^5019280
 ;;^UTILITY(U,$J,358.3,33805,0)
 ;;=I87.003^^191^1976^14
 ;;^UTILITY(U,$J,358.3,33805,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33805,1,3,0)
 ;;=3^Postthrom syndr w/o compl of bilat lwr extrem
 ;;^UTILITY(U,$J,358.3,33805,1,4,0)
 ;;=4^I87.003
 ;;^UTILITY(U,$J,358.3,33805,2)
 ;;=^5008029
 ;;^UTILITY(U,$J,358.3,33806,0)
 ;;=I87.001^^191^1976^13
 ;;^UTILITY(U,$J,358.3,33806,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33806,1,3,0)
 ;;=3^Postrhomb syndr w/o compl of rt lwr extrem
 ;;^UTILITY(U,$J,358.3,33806,1,4,0)
 ;;=4^I87.001
 ;;^UTILITY(U,$J,358.3,33806,2)
 ;;=^5008027
 ;;^UTILITY(U,$J,358.3,33807,0)
 ;;=I73.9^^191^1976^3
 ;;^UTILITY(U,$J,358.3,33807,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33807,1,3,0)
 ;;=3^Peripheral vascular disease, unspec
 ;;^UTILITY(U,$J,358.3,33807,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,33807,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,33808,0)
 ;;=I80.01^^191^1976^9
 ;;^UTILITY(U,$J,358.3,33808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33808,1,3,0)
 ;;=3^Phlebitis & Thromboph,Right Lower Sprfcl Vessels
 ;;^UTILITY(U,$J,358.3,33808,1,4,0)
 ;;=4^I80.01
 ;;^UTILITY(U,$J,358.3,33808,2)
 ;;=^5007821
 ;;^UTILITY(U,$J,358.3,33809,0)
 ;;=I80.02^^191^1976^7
 ;;^UTILITY(U,$J,358.3,33809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33809,1,3,0)
 ;;=3^Phlebitis & Thromboph,Left Lower Sprfcl Vessels
 ;;^UTILITY(U,$J,358.3,33809,1,4,0)
 ;;=4^I80.02
 ;;^UTILITY(U,$J,358.3,33809,2)
 ;;=^5007822
 ;;^UTILITY(U,$J,358.3,33810,0)
 ;;=I80.03^^191^1976^5
 ;;^UTILITY(U,$J,358.3,33810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33810,1,3,0)
 ;;=3^Phlebitis & Thromboph,Bilateral Lower Sprfcl Vessels
 ;;^UTILITY(U,$J,358.3,33810,1,4,0)
 ;;=4^I80.03
 ;;^UTILITY(U,$J,358.3,33810,2)
 ;;=^5007823
 ;;^UTILITY(U,$J,358.3,33811,0)
 ;;=I80.11^^191^1976^8
 ;;^UTILITY(U,$J,358.3,33811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33811,1,3,0)
 ;;=3^Phlebitis & Thromboph,Right Femoral Vein
 ;;^UTILITY(U,$J,358.3,33811,1,4,0)
 ;;=4^I80.11
 ;;^UTILITY(U,$J,358.3,33811,2)
 ;;=^5007825
 ;;^UTILITY(U,$J,358.3,33812,0)
 ;;=I80.12^^191^1976^6
 ;;^UTILITY(U,$J,358.3,33812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33812,1,3,0)
 ;;=3^Phlebitis & Thromboph,Left Femoral Vein
 ;;^UTILITY(U,$J,358.3,33812,1,4,0)
 ;;=4^I80.12
 ;;^UTILITY(U,$J,358.3,33812,2)
 ;;=^5007826
 ;;^UTILITY(U,$J,358.3,33813,0)
 ;;=I80.13^^191^1976^4
 ;;^UTILITY(U,$J,358.3,33813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33813,1,3,0)
 ;;=3^Phlebitis & Thromboph,Bilateral Femora Vein
 ;;^UTILITY(U,$J,358.3,33813,1,4,0)
 ;;=4^I80.13
 ;;^UTILITY(U,$J,358.3,33813,2)
 ;;=^5007827
 ;;^UTILITY(U,$J,358.3,33814,0)
 ;;=L98.0^^191^1976^23
 ;;^UTILITY(U,$J,358.3,33814,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33814,1,3,0)
 ;;=3^Pyogenic granuloma
 ;;^UTILITY(U,$J,358.3,33814,1,4,0)
 ;;=4^L98.0
 ;;^UTILITY(U,$J,358.3,33814,2)
 ;;=^5009574
 ;;^UTILITY(U,$J,358.3,33815,0)
 ;;=L40.0^^191^1976^18
 ;;^UTILITY(U,$J,358.3,33815,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33815,1,3,0)
 ;;=3^Psoriasis vulgaris
